Romosozumab
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Romosozumab is listed as bone / sclerostin inhibitor.
- •Postmenopausal Osteoporosis
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Romosozumab; also known as Evenity.
Pharmacologic class: Bone / Sclerostin Inhibitor.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Anti-sclerostin monoclonal antibody — dual action: increases bone formation AND decreases resorption simultaneously.
- •Rapid and substantial BMD gains
- •Reduced vertebral and clinical fractures
- •Short 12-month course
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III FRAME / ARCH trials.
Laboratory Research
Phase III FRAME / ARCH trials
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Monthly SubQ (2 injections back-to-back). Same day each month.
Potential interactions and combinations to avoid
- •Recent MI or stroke — cardiovascular boxed warning
- •Concurrent PTH analogs
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •MI/stroke (black box CV warning)
- •Jaw osteonecrosis
- •Atypical femoral fractures
- •Hypocalcemia
Contraindications
- •Recent MI or stroke (1 year)
- •Hypocalcemia
- •Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- •History of skeletal radiation therapy or osteosarcoma
- •Unexplained elevated alkaline phosphatase or bone metastases
- •Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- •Severe renal impairment or active kidney stone disease
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 210 mg/month
Frequency: Monthly (12 doses)
Cycling: 12 monthly doses, then transition to antiresorptive.
Subcutaneous
Monthly, 2 injections back-to-back.
Two pre-filled syringes (105 mg each). Abdomen, thigh, or outer upper arm; give both injections at once, one per site.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Followed by bisphosphonate or denosumab after 12 months
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Monthly clinical injection — time of day not relevant.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
12 monthly doses, then transition to antiresorptive.
Timing & Interactions
- ·Recent MI or stroke — cardiovascular boxed warning
- ·Concurrent PTH analogs
- ·Followed by bisphosphonate or denosumab after 12 months
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Romosozumab and sync them to Vial Lab.
Benefits
- ·Rapid and substantial BMD gains
- ·Reduced vertebral and clinical fractures
- ·Short 12-month course
Risks
- ·MI/stroke (black box CV warning)
- ·Jaw osteonecrosis
- ·Atypical femoral fractures
- ·Hypocalcemia
Contraindications
- ·Recent MI or stroke (1 year)
- ·Hypocalcemia
- ·Hypercalcemia, hyperparathyroidism, or Paget's disease of bone
- ·History of skeletal radiation therapy or osteosarcoma
- ·Unexplained elevated alkaline phosphatase or bone metastases
- ·Myocardial infarction or stroke within the previous 12 months (sclerostin inhibitors)
- ·Severe renal impairment or active kidney stone disease
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Romosozumab. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.